Please login to the form below

Not currently logged in
Email:
Password:

Apitope strengthens its board with new director

Dr William Jenkins joins the board following a 30-year career in clinical medicine

Dr William JenkinsClinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.

He has also served on several boards including Ablynx, Evotec and Acambis.

Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.

“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.

“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”

22nd March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...
White paper: The impact of COVID-19 on chronic disease management
...

Infographics